6-O-Angeloylplenolin Induces Mitotic Arrest and Exhibits Therapeutic Potentials in Multiple Myeloma
Author Information
Author(s): Liu Ying, Chen Xiao-Qin, Liang Heng-Xing, Zhang Feng-Xiang, Zhang Bo, Jin Jie, Chen Yong-Long, Cheng Yong-Xian, Zhou Guang-Biao
Primary Institution: Guangzhou Institute of Biomedicine and Health and State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
Hypothesis
The study investigates the effects and mechanisms of action of 6-O-angeloylplenolin (6-OAP) on multiple myeloma (MM) cells.
Conclusion
6-OAP is a new cell cycle inhibitor that shows therapeutic potential for multiple myeloma.
Supporting Evidence
- 6-OAP suppressed the proliferation of both dexamethasone-sensitive and dexamethasone-resistant cell lines.
- 6-OAP caused mitotic arrest and activated the spindle assembly checkpoint.
- Combined use of 6-OAP and bortezomib induced enhanced cytotoxicity.
- 6-OAP inhibited the protective effects of IL-6 and IGF-I on MM cells.
Takeaway
This study found that a natural compound called 6-OAP can stop cancer cells from growing and might help treat a type of blood cancer called multiple myeloma.
Methodology
MM cells were treated with 6-OAP, and cell cycle distribution was analyzed; the effects of 6-OAP on MM cells were evaluated using various assays including MTT and trypan blue exclusion.
Participant Demographics
CD138+ cells from 7 multiple myeloma patients and peripheral blood mononuclear cells from 5 healthy volunteers.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website